What if you could predict placebo responsiveness of each patient in your clinical trial? Historical strategies to address the placebo response may help but haven’t completely solved the placebo response problem. Until now. Advanced methods like AI and machine learning are uniquely poised to help scientists uncover the full spectrum of patient placebo responsiveness in a clinical trial. Learn more about this approach by attending our webinar, which explains how a solution like Placebell©™ leverages a time-tested predictive algorithm to improve clinical trial assay sensitivity and de-risk drug development.Read More
With 2020 coming to a close, it is an opportune time to pause and reflect on the progress we have made as an industry, as a company and as individuals. We congratulate our partners and friends for their ingenuity and perseverance in rising to the challenges of the year.Read More
“Stratification of patients based on the neuropathic pain symptom inventory (NPSI): development and validation of a new algorithm” published in Pain.
The journal article “Stratification of patients based on the neuropathic pain symptom inventory (NPSI): development and validation of a new algorithm”, has been published ahead of print in the journal Pain. This article was authored by Didier Bouhassira, MD, Director of Research at the National Institute for Health and Medical Research (INSERM) in France and member of Tools4Patient’s scientific advisory board, and was co-authored by Tools4Patient scientists Samuel Branders PhD, Alvaro Pereira PhD and Dominique Demolle, PhD.Read More
The Placebo Response: A Hidden Risk to COVID-19 Trials” – First Opinion written by Tools4Patient authors published in STAT News
STAT News published “The Placebo Response: A Hidden Risk to COVID-19 Trials” written by Tools4Patient authors on October 13, 2020. The article, authored by Erica Smith PhD, VP of Business Development and Dominique Demolle PhD, CEO, was published in STAT’s First Opinion column. The article asserts that the success of the abundant drug development program for COVID-19 therapiesRead More
The Tools4Patient team has moved our offices to a new building located in the same scientific campus in Louvain-La-Neuve, Belgium in early September, 2020. The rapid expansion of collaborations with innovative biopharma companies has led to 30% growth of our team – particularly in scientific and operational support areas – over the last year.Read More
Tools4Patient Introduces unik-me Platform for Administration of Psychological Questionnaires in Clinical Trials
Tools4Patient (T4P) introduces unik-me, our proprietary platform to administer psychological questionnaires to patients in clinical trials.Read More
Tools4Patient launches COV-IQ to evaluate the impact of the COVID-19 pandemic on patients in ongoing clinical trials
Tools4Patient launches COV-IQ, a new platform aiming to evaluate the impact of COVID-19 on clinical trial patients. COV-IQ aims to quantify the effect of emotional stress, change in trial conduct and changes in social structure on each trial subject.Read More
“Modeling of Peripheral Neuropathic Pain and Osteoarthritis Placebo Response” presented at the International Society for CNS Clinical Trials and Methodology
Dr. Dominique Demolle, CEO of Tools4Patient, recently presented data at the 16th Annual Scientific Meeting of the International Society for CNS Clinical Trials and Methodology in Washington, DC. The presentation, entitled ““Modeling of Peripheral Neuropathic Pain and Osteoarthritis Placebo Response: Working Towards a Unique Model of the Placebo Response in Chronic Pain?” was authored by Tools4Patient scientist Dr. SamuelRead More
Tools4Patient’s Placebell©™ technology has been selected as a finalist in the 2019 Clinical Trials Innovation Challenge sponsored by IQVIA, Lundbeck, and LEO Innovation Lab.Read More
“Sensory Profiles and stratification of neuropathic pain patients based on the neuropathic pain symptom inventory (NPSI)” presented at the 2019 European Pain Federation EFIC Conference.
This study aimed to identify specific sensory phenotypes of peripheral neuropathic pain patients that could predict treatment response based on pain symptoms assessed by the Neuropathic Pain Symptom Inventory (NPSI).Read More